Cel-Sci Corporation News
Cramer's Mad Money Recap 10/18: Crude, Bitcoin, Amazon, Apple
Rising crude oil prices, Bitcoin, tech stocks and housing: Jim Cramer says not everything can go up at the same time.
CEL-SCI Tumbles After Study Misses Primary Endpoint
Trading in CEL-SCI is halted at least three times as its share price falls rapidly.
'Mad Money' Lightning Round: Amazon, Walgreens and More
Jim Cramer’s bullish on Amazon, but isn't recommending Equinix or Walgreens Boots Alliance.
Bottom Fishing?: Cramer's 'Mad Money' Recap (Thursday 3/4/21)
There are different ways to spot a market bottom, Jim Cramer says, but we aren't there yet. Here's why.
Rally With Caution: Cramer's 'Mad Money' Recap (Tuesday 2/4/20)
Jim Cramer has his reservations about news on the coronavirus and the Chinese economy, and says investors should approach this rally with caution.
PayPal, NextEra Energy, Sarepta Therapeutics: 'Mad Money' Lightning Round
Jim Cramer takes a look at PayPal, NextEra Energy, Sarepta Therapeutics, CEL-SCI, MFA Financial, Fidelity National Services and more.
Biotech movers: CEL-SCI Leaps After FDA Lets Cancer Study Move Forward
The last FDA approved treatment for advanced primary head and neck cancer was over 50 years ago.
A Neurotrope Stock Promotion Scheme Is Underway, but Who's Paying for It?
Sharon di Stefano loves Neurotrope but doesn't know how her Seeking Alpha articles are being transformed into stock-promoting press releases.
What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016
TheStreet's biotech columnist offers his own report card on biotech stocks.